Document:

Exhibit 4.1

 

DESCRIPTION OF REGISTRANT’S
SECURITIES

 

The following summary of Greenrose Acquisition
Corp.’s securities is based on and qualified by the Company’s Amended and Restated Articles of Incorporation (the “Amended
and Restated Charter”). References to the “Company” and to “we,” “us,” and “our”
refer to Greenrose Acquisition Corp.

 

General

 

As of December 31, 2020, the Company is
authorized to issue 70,000,000 shares of common stock, par value $0.0001, and 1,000,000 shares of preferred stock, par value $0.0001.
There are no shares of preferred stock currently outstanding.

 

Units

 

As of December 31, 2020, were 17,250,000
public units outstanding. Each unit consists of one share of common stock and one warrant. Each warrant entitles the holder to
purchase one share of common stock. On May 11, 2020, the shares of common stock and warrants included in the units began separate
trading. Holders of units have the option to continue to hold the units or separate the units into the component pieces.

 

Common Stock

 

At December 31, 2020, there were 21,892,500
issued and outstanding shares of common stock. Our stockholders of record are entitled to one vote for each share held on all matters
to be voted on by stockholders. In connection with any vote held to approve our initial business combination, our Sponsor, as well
as all of our officers and directors, have agreed to vote their respective shares of common stock owned by them immediately prior
to our IPO (the “founder’s common stock”) and any shares purchased following the IPO in the open market in favor
of any proposed business combination.

 

Our board of directors is divided into
three classes, each of which will generally serve for a term of three years with only one class of directors being elected in each
year. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50%
of the shares eligible to vote for the election of directors can elect all of the directors.

 

Pursuant to our Amended and Restated Charter,
if we do not consummate an initial business combination by August 13, 2021 (unless such date is extended by our Sponsor for up
to an additional 3 months by depositing funds in our trust account or stockholders pursuant to an amendment to our Amended and
Restated Charter), our corporate existence will cease except for the purposes of winding up our affairs and liquidating and we
will redeem 100% of our outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate
amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously
released to us, divided by the number of then outstanding public shares, subject to applicable law and as further described herein.
Our Sponsor, officers and directors have agreed to waive their rights to participate in any liquidation distribution from the trust
account occurring upon our failure to consummate an initial business combination with respect to the founder’s common stock.
Our Sponsor, officers and directors will therefore not participate in any liquidation distribution from the trust account with
respect to such shares. They will, however, participate in any liquidation distribution from the trust account with respect to
any shares of common stock acquired after our IPO.

 

Our stockholders have no conversion, preemptive
or other subscription rights and there are no sinking fund or redemption provisions applicable to the shares of common stock, except
that public stockholders have the right to sell their shares to us in a tender offer or have their shares of common stock converted
to cash equal to their pro rata share of the trust account if they vote on the proposed business combination in connection with
such business combination and the business combination is completed. Public stockholders who sell or convert their stock into their
share of the trust account still have the right to exercise the warrants that they received as part of the units.

 

If we seek to amend any provisions of our
Amended and Restated Charter that would affect our public stockholders’ ability to convert their shares in connection with
a business combination or affect the substance or timing of our obligation to redeem 100% of our public shares if we do not complete
a business combination by the required date set forth in our Amended and Restated Charter, we will provide public stockholders
with the opportunity to convert their public shares in connection with any such vote. This conversion right shall apply in the
event of the approval of any such amendment, whether proposed by our Sponsor, any executive officer, director or director nominee,
or any other person. 

 

     

     

    

 

Preferred Stock

 

There are no shares of preferred stock
outstanding. Our Amended and Restated Charter authorizes the issuance of 1,000,000 shares of preferred stock with such designation,
rights and preferences as may be determined from time to time by our board of directors. Our board of directors is empowered, without
stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely
affect the voting power or other rights of the holders of common stock. However, the underwriting agreement prohibits us, prior
to a business combination, from issuing preferred stock which participates in any manner in the proceeds of the trust account,
or which votes as a class with the common stock on a business combination. We may issue some or all of the preferred stock to effect
a business combination. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing
a change in control of us. Although we do not currently intend to issue any shares of preferred stock, we cannot assure you that
we will not do so in the future.

 

Warrants

 

As of December 31, 2020, there were 19,230,000
warrants outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per
share, subject to adjustment as discussed below, at any time commencing 30 days after the completion of an initial business combination.
 However, no warrants will be exercisable for cash unless we have an effective and current registration statement covering
the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to such shares of common stock.
Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the public
warrants is not effective within a specified period following the consummation of our initial business combination, warrant holders
may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain
an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9)
of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders
will not be able to exercise their warrants on a cashless basis. In the event of such a cashless exercise, each holder would pay
the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing
(x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise
price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market
value” for this purpose will mean the average reported last sale price of the shares of common stock for the 5 trading days
ending on the trading day prior to the date of exercise. The warrants will expire on the fifth anniversary of our completion of
an initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

 

The warrants included in the units issued
privately concurrently with our IPO (the “private warrants”), as well as any warrants underlying additional units we
issue to our Sponsor, officers, directors or their affiliates in payment of working capital loans made to us, will be identical
to the warrants underlying the units offered in our IPO except that such warrants will be exercisable for cash or on a cashless
basis, at the holder’s option, and will not be redeemable by us, in each case so long as they are still held by our Sponsor
or its permitted transferees.

 

We may call the warrants for redemption
(excluding the private warrants and any warrants underlying additional units issued to our Sponsor, initial stockholders, officers,
directors or their affiliates in payment of working capital loans made to us), in whole and not in part, at a price of $0.01 per
warrant, (i) at any time after the warrants become exercisable, (ii) upon not less than 30 days’ prior written notice of
redemption to each warrant holder after the warrants become exercisable, (iii)  if, and only if, the reported last sale price
of the shares of common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations
and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable
and ending on the third business day prior to the notice of redemption to warrant holders, and (iv) if, and only if, there is a
current registration statement in effect with respect to the shares of common stock underlying such warrants.

 

    	 	2	 

     

    

 

The right to exercise will be forfeited
unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a
record holder of a warrant will have no further rights except to receive the redemption price for such holder’s warrant upon
surrender of such warrant.

 

If we call the warrants for redemption
as described above, our management will have the option to require all holders that wish to exercise warrants to do so on a “cashless
basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of
common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the
warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined
below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last
sale price of the shares of common stock for the 5 trading days ending on the third trading day prior to the date on which the
notice of redemption is sent to the holders of warrants.

 

The exercise price and number of shares
of common stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock
dividend, extraordinary dividend or our recapitalization, reorganization, merger or consolidation. However, except as described
below, the warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices.

 

In addition, if (x) we issue additional
shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial
business combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price
or effective issue price to be determined in good faith by our board of directors, and in the case of any such issuance to our
Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to
such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and
interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial
business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the warrants
will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which we
issue the additional shares of common stock or equity-linked securities. The “Market Value” for this purpose means
the volume weighted average trading price of our common stock during the 20 trading day period starting on the trading day prior
to the day on which we consummate our initial business combination.

 

No fractional shares will be issued upon
exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share,
we will, upon exercise, round up to the nearest whole number the number of shares of common stock to be issued to the warrant holder.

 

Dividends

 

We have not paid any cash dividends on
our shares of common stock to date and do not intend to pay cash dividends prior to the completion of a business combination. The
payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general
financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to a business combination
will be within the discretion of our then board of directors. It is the present intention of our board of directors to retain all
earnings, if any, for use in our business operations and, accordingly, our board does not anticipate declaring any dividends in
the foreseeable future.

 

Listing of Securities

 

Our units, common stock and warrants are
listed on the Nasdaq Capital Market under the symbols “GNRSU,” “GNRS,” and “GNRSW,” respectively.

 

    	 	3	 

     

    

 

Delaware Anti-Takeover La

 

Staggered Board of Directors

 

Our Amended and Restated Charter provides
that our board of directors will be classified into three classes of directors of approximately equal size. As a result, in most
circumstances, a person can gain control of our board only by successfully engaging in a proxy contest at two or more annual meetings.

 

Special Meeting of Stockholders

 

Our bylaws provide that special meetings
of our stockholders may be called only by a majority vote of our board of directors, by our president or by our chairman or by
our secretary at the request in writing of stockholders owning a majority of our issued and outstanding capital stock entitled
to vote.

 

Advance Notice Requirements for Stockholder
Proposals and Director Nominations

 

Our bylaws provide that stockholders seeking
to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual
meeting of stockholders must provide timely notice of their intent in writing. To be timely, a stockholder’s notice will
need to be delivered to our principal executive offices not later than the close of business on the 60th day nor
earlier than the close of business on the 90th day prior to the scheduled date of the annual meeting of stockholders.
In the event that less than 70 days’ notice or prior public disclosure of the date of the annual meeting of stockholders
is given, a stockholder’s notice shall be timely if delivered to our principal executive offices not later than the 10th day
following the day on which public announcement of the date of our annual meeting of stockholders is first made or sent by us. Our
bylaws also specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude
our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our
annual meeting of stockholders.

 

Authorized but Unissued Shares

 

Our authorized but unissued common stock
and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate
purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized
but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control
of us by means of a proxy contest, tender offer, merger or otherwise.

 

Exclusive Forum Selection

 

Our Amended and Restated Charter requires,
to the fullest extent permitted by law, that derivative actions brought in our name, actions against directors, officers and employees
for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware, except
any action (A) as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject
to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the
Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or
forum other than the Court of Chancery, (C) for which the Court of Chancery does not have subject matter jurisdiction or (D) any
action arising under the Securities Act, as to which the Court of Chancery and the federal district court for the District of Delaware
shall have concurrent jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed
to have consented to service of process on such stockholder’s counsel. Although we believe this provision benefits us by
providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, a court may determine
that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits
against our directors and officers, although our stockholders will not be deemed to have waived our compliance with federal securities
laws and the rules and regulations thereunder and therefore bring a claim in another appropriate forum. Additionally, we cannot
be certain that a court will decide that this provision is either applicable or enforceable, and if a court were to find the choice
of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an
action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business,
operating results and financial condition.

 

Our Amended and Restated Charter provides
that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law. Section 27 of the Exchange
Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act
or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce
any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

 

4Exhibit 4.7

 

 

SALE AGENCY AGREEMENT

 

BETWEEN

 

ADDEX THERAPEUTICS

 

AND

 

KEPLER CHEUVREUX

 

	
Kepler Cheuvreux S.A.
    	
http://www.keplercheuvreux.com/
    	
Tél   : +33 1 53 65 35 00
    	
Société   anonyme
    
	
Siège   social :
    	
 
    	
 
    	
au   capital de 54.744.920 €
    
	
112   avenue Kléber
    	
 
    	
 
    	
RCS   Paris B 413 064 841, APE 652 E
    
	
75784   Paris Cedex 16
    	
 
    	
 
    	
Identification   TVA FR 38413064841
    
	
France
    	
 
    	
 
    	
Entreprise   d’investissement régie par la loi n° 96-597
    
	
 
    	
 
    	
 
    	
du   02.07.96
    

 

 

THIS AGREEMENT (the “Agreement”) IS MADE BY AND BETWEEN:

 

ADDEX THERAPEUTICS SA, a company with share capital of [CHF 32,848,635], having its registered office at Chemin des Aulx 12, CH 1228 Plan-les-Quates, Switzerland listed on the Commercial Registry of Canton of Geneva under the number CH-660.0.659.007-3, represented by Tim Dyer as Chief Executive Officer,

 

(hereinafter referred to as “the Client”),

 

AND:

 

KEPLER CHEUVREUX, a French Société Anonyme (share company), registered on the Paris Register of Companies with the number 413 064 841, whose registered office is located at 112, avenue Kléber, 75116 Paris, represented by Julia ALICHE as Chief Operating Officer and Guillaume CADIOU as General Group Manager,

 

(hereinafter referred to as “Kepler Cheuvreux”),

 

Kepler Cheuvreux and the Client are collectively referred to as the “Parties”.

 

WHEREAS:

 

·                                The Client wishes to carry out the sale of up to 5,000,000 registered shares of Addex Therapeutics SA (the “Shares”).

 

·                                The Shares are admitted for trading on SIX Swiss Exchange (hereinafter called the “Exchange”) with the trading code ISIN CH0029850754.

 

·                                Therefore, the Client wishes to engage Kepler Cheuvreux with the sale of the Shares under the conditions determined by the present Agreement and in accordance with the general terms and conditions of business which are in effect at Kepler Cheuvreux. In the event of any contradictions between the terms of the said general terms and conditions of business and those of the present Agreement, the terms of the Agreement shall prevail.

 

2

 

IT IS HEREBY AGREED THAT:

 

Article 1 — SALE AGENCY AGREEMENT

 

In accordance with the terms hereof, Kepler Cheuvreux is authorized to sell up to 5,000,000 Shares on behalf of the Client.

 

Article 2 — TERMS OF THE SALE OF THE SHARES

 

2.1                               Open market transactions:

 

Kepler Cheuvreux will make its best efforts to sell the Shares on the central order book of the Exchange, on behalf of the Client and in accordance with the rules of the Exchange; with the following restrictions:

 

·                  Minimum gross price per Share will be communicated by the Client by e-mail to Kepler Cheuvreux. Such price may be modified by telephone and shall be confirmed by an email by a person of Kepler Cheuvreux authorized by the Client at any time time, except during blackout periods

·                  [***]

·                  No sale if daily volume is below [***] shares

 

2.2                               Block transactions carried outside the Exchange central order book:

 

In addition, Kepler Cheuvreux will make its best efforts to sell Shares by block transactions outside the central book of the Exchange.

 

Outside of Black-out periods, the Client can provide Kepler Cheuvreux with potential counterparts, with whom Kepler Cheuvreux will do its best efforts to sell Shares by block transactions.

 

The selling price for block transactions shall follow the same restrictions as in 2.1.

 

2.3                               Apart from the general instructions listed in this article and subject to price adjustment provided in article 2.1 and to article 5 below, the Client shall not issue any further instructions. Kepler Cheuvreux shall make its trading decisions in relation to the sale of Shares independently of, and without influence by the Client with regard to the timing of the sales.

 

Article 3 — Commissions

 

3.1                               Brokerage fee:

 

Kepler Cheuvreux shall receive a brokerage fee (excluding VAT and any securities transactions tax) equal to 0.75% of the gross proceeds from the sale of the Shares. It is the Client’s sole responsibility to determine if transfer stamp duties apply. The Client shall pay any transfer stamp duties directly to the Swiss fiscal authorities if and when applicable.

 

3

 

3.2                               Success fee:

 

In addition, if at the end of the mandate, the averge gross selling price of the Shares is above the volume weighted average price (“VWAP”) of the Shares over the duration of the Agreement, Kepler Cheuvreux will be entitled to a success fee equal to:

 

0.15 x number of Shares sold x (average selling price per Share — VWAP)

 

Article 4 — DURATION

 

The Agreement will be effective as of its date of signature until March 31st 2021 unless terminated earlier by either Party.

 

Article 5 — SUSPENSION AND TERMINATION

 

5.1.                            Each of the Parties shall be entitled to terminate the Agreement at any time, without penalty and without being required to provide a reason therefore. Notification of termination shall be given to the other Party by letter, fax or email.

 

5.2.                            Termination by the Client will take effect upon receipt of the above-mentioned notification by Kepler Cheuvreux.

 

5.3.                            Termination by Kepler Cheuvreux will take effect five Exchange trading days after the date on which the notification is sent to the Client.

 

5.4.                            The Client shall be entitled to suspend the Agreement at any time, except during blackout periods.

 

Article 6 — DECLARATION AND COMMITMENTS OF THE CLIENT

 

6.1                               The Client hereby declares that it has full knowledge of the applicable regulations in effect concerning the use of inside information and the sanctions applicable in the event of non-compliance with applicable regulations.

 

6.2                               Moreover, the Client hereby declares that it does not possess, at the date of signature of the Agreement, privileged information, within the meaning of the applicable regulations.

 

6.3                               The Client hereby undertakes to respect all registration and notification obligations relating to the sale of the Shares in compliance with any applicable law.

 

6.4                               The Client declares that this Agreement has been duly authorized and executed by its competent authority and constitutes valid and legally binding obligations of the Client enforceable in accordance with its terms. The making of this Agreement and the compliance with the terms hereof will not result in violation of the Client’s constitutive documents or any provision contained in any law applicable to the Client. The Client will maintain all necessary consents and authorizations for the sale of Shares contemplated by this Agreement.

 

4

 

Article 7 — NOTIFICATION

 

All notification shall be made to the following addresses:

 

· For KEPLER CHEUVREUX:

 

Cyril GERARD

Head of Corporate Brokerage Kepler Cheuvreux

112 av. Kleber

75116 Paris France

+33170815808

Email address: cgerard@keplercheuvreux.com

 

·  For ADDEX THERAPEUTICS:

 

Tim Dyer

CEO

Addex Therapeutics Ltd

Chemin des Aulx 14

CH1228 Plan-les-Oautes

Geneva, Switzerland

+41228841555

Email address :  tim.dyer@addexpharma.com

 

Article 8 — APPLICABLE LAW

 

The Agreement shall be governed by the substantive laws of Switzerland.

 

Article 9 — SETTLEMENT OF DISPUTES

 

The courts of Zurich, Canton of Zurich, Switzerland shall have sole jurisdiction over all disputes arising out of or in connection with the Agreement.

 

Article 10 - ASSIGNMENT

 

Neither Party may assign or transfer any rights or obligations under this Agreement to any person except that Kepler Cheuvreux may assign any rights or transfer any obligations under this Agreement to any of its affiliates.

 

5

 

IN WITHNESS WHEREOF, this Agreement is executed on 24/08/2020

 

For ADDEX THERAPEUTICS

 

	
/s/ Tim Dyer
    	
 
    	
 
    
	
Tim Dyer
    	
 
    	
 
    
	
CEO
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
For   KEPLER CHEUVREUX
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Julia ALICHE
    	
 
    	
/s/   Guillaume CADIOU
    
	
Julia ALICHE
    	
 
    	
Guillaume   CADIOU
    
	
Chief Operating   Officer
    	
 
    	
General Group Manager
    

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]